Double blind comparative study of effects of amino acids in patient with cognitive dementia

Double blind comparative study of effects of amino acids in patient with cognitive dementia - Evaluation of effects of amino acids in patient with dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027186

Enrollment

Registered

2017-06-01

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia

Interventions

Placebo Amino Acids

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Mild Alzheimer's disease. 2)Patients with neuropsychiatric symptom. 3)Agreement available with proxy. 4)Antidementia drugs treatment over 4 weeks or no treatment of antidementia drugs.

Exclusion criteria

Exclusion criteria: 1)Taking supplements in major components of amino acids, DHA, EPA and ginko leaf extract. Taking Chinese medicine including YOKUKANSAN. 2)Less than 6 years of schooling history. 3)Alcholic poisoning or under treatment of it 4)Under treatment of cancer of cirrhosis. 5)Getting artificial dialysis. 6)Patients taking medicine for neuropsychiatric disorder, however, that this shall not apply when dose of these drugs are stable. 7)Soy allergy. 8)Patients that representative or sub investigator determine inappropriate.

Design outcomes

Primary

Measure	Time frame
neuropsychiatric symptom	—

Countries

Japan

Contacts

Public ContactShin Tanaka

Specified medical corporation, Rakuzankai, Mishima-hosipital Psychiatry

shin_tanaka39@hotmail.com0258-42-2311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026